In patients with breast cancer treated with anthracycline-based chemotherapy and trastuzumab, the expression of endothelin-1 in breast tumor tissue may predict chemotherapy-induced cardiotoxicity as greater expression was seen in patients with LVEF ≤50% and with a greater reduction in LVEF ≥10% from baseline. Here, EDN1 is linked to breast neoplasm.